Antibodies to factor VIII in hemophilia A patients.
Inhibitor development represents the main complication in the treatment of haemophilia A. The risk of inhibitor formation is in part genetically determined by the type of the underlying factor VIII gene lesion but environmental factors may also play an important role. Due to the lack of efficiency of factor VIII in these patients other therapeutic agents must be used for the treatment of bleedings, however, none is as effective as factor VIII in a non-inhibitor patient. Therefore, the eridication of the inhibitor through immune tolerance therapy is the treatment of choice. Centralized national and international immune tolerance registries have collected the results and show cost effectiveness of this treatment.
Brackmann
H H
HH
Institute for Experimental Hematology and Transfusion Medicine, University Bonn.
Schwaab
R
R
Effenberger
W
W
Hess
L
L
Hanfland
P
P
Oldenburg
J
J
D005169:Factor VIII / Q000276:immunology* / Q000627:therapeutic use; D006467:Hemophilia A / Q000097:blood / Q000150:complications / Q000276:immunology*; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007108:Immune Tolerance; D007518:Isoantibodies / Q000097:blood*; D012042:Registries
D007518:Isoantibodies; D005169:Factor VIII